Navigating the Changing Landscape in the Treatment and Management of Acute Myeloid Leukemia (AML): Key Considerations in Managed Care Decision-Making

Navigating the Changing Landscape in the Treatment and Management of Acute Myeloid Leukemia (AML): Key Considerations in Managed Care Decision-Making is organized by National Association of Managed Care Physicians (NAMCP).,,This activity is valid from June 1, 2022, to August 1, 2023,,Description:,Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 19,940 new cases of AML and 11,180 deaths from AML in the United States in 2020. The five-year survival rate has not improved in older patients despite of 40 years of research. Fortunately for patients with AML, many new treatments have recently been approved for use. These options, which are among the first new treatments in AML since 1990, have begun to drastically change the treatment paradigm. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the AML patient population.,,Upon completion of this activity, participants will be able to:,• Assess the clinical and economic burden of AML, including factors that contribute to poor prognosis and increased costs,• Evaluate recent data on the efficacy and safety of novel therapeutics in AML in a range of patient populations,• Examine the evolving role of DNA hypomethylating agents in the management of patients with AML,• Explain how maintenance therapy is used as part of the AML treatment paradigm,• Assess novel treatment approaches in the context of evolving treatment paradigms in the management of AML including methods to personalize care for elderly patients or those with poor performance status in a COVID-19 environment,• Employ interventions such as clinical pathways and site of care initiatives for optimal cost management and improved outcomes in AML.